Literature DB >> 22880840

Follow-up of gynecological cancer patients after treatment - the views of European experts in gynecologic oncology.

Ingvild Vistad1, Milada Cvancarova, Helga B Salvesen.   

Abstract

OBJECTIVE: Follow-up after treatment for gynecological cancer demands large resources. There is a lack of evidence of efficacy. The aim of this survey was to explore follow-up routines and views on follow-up care among European experts in gynecological oncology.
DESIGN: Web-based structured survey.
SETTING: Survey distributed to members of the European Society of Gynecological Oncology (ESGO) and the Nordic Society of Gynecologic Oncology (NSGO). POPULATION: The study population comprised members of NSGO and ESGO.
METHODS: An anonymous e-survey was sent with two additional reminders by e-mail through an electronic web-link to all members of both societies. MAIN OUTCOME MEASURES: Surveillance routines. The clinical experts' evaluation of evidence and view of follow-up in hospitals vs. at general practitioners (GPs).
RESULTS: The number of visits recommended by a majority of the responders was in line with current guidelines. The use of surveillance tests varied considerably. Significantly more responders from low economy countries preferred conventional hospital follow-up for all patients compared with responders from high economy countries, who considered follow-up by GPs adequate in low-risk groups (p < 0.001).
CONCLUSIONS: Follow-up routines after gynecological cancer vary in Europe. According to the majority of the responders of this survey targeting European experts in gynecological oncology, follow-up by GPs may be an option for low-risk patients. New follow-up routines should preferentially be based on prospective trials comparing conventional follow-up of gynecological cancer patients with alternative methods of care, assessing survival, detection of recurrence, and quality of life.
© 2012 The Authors Acta Obstetricia et Gynecologica Scandinavica© 2012 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22880840     DOI: 10.1111/j.1600-0412.2012.01523.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  2 in total

1.  The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.

Authors:  David Cibula; Lukáš Dostálek; Jiri Jarkovsky; Constantijne H Mom; Aldo Lopez; Henrik Falconer; Anna Fagotti; Ali Ayhan; Sarah H Kim; David Isla Ortiz; Jaroslav Klat; Andreas Obermair; Fabio Landoni; Juliana Rodriguez; Ranjit Manchanda; Jan Kosťun; Ricardo Dos Reis; Mehmet M Meydanli; Diego Odetto; Rene Laky; Ignacio Zapardiel; Vit Weinberger; Klára Benešová; Martina Borčinová; Darwin Pari; Sahar Salehi; Nicolò Bizzarri; Huseyin Akilli; Nadeem R Abu-Rustum; Rosa A Salcedo-Hernández; Veronika Javůrková; Jiří Sláma; Luc R C W van Lonkhuijzen
Journal:  Eur J Cancer       Date:  2021-10-16       Impact factor: 10.002

2.  Gynaecological cancer follow-up: national survey of current practice in the UK.

Authors:  Simon Leeson; Nick Stuart; Yvonne Sylvestre; Liz Hall; Rhiannon Whitaker
Journal:  BMJ Open       Date:  2013-07-24       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.